Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioCryst off after peramivir miss

BCRX was off $3.78 (32%) to $8 on Thursday after reporting

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE